Burney Co. Purchases Shares of 12,345 Globus Medical, Inc. $GMED

Burney Co. acquired a new stake in Globus Medical, Inc. (NYSE:GMED) in the first quarter, HoldingsChannel.com reports. The firm acquired 12,345 shares of the medical device company’s stock, valued at approximately $1,064,000.

Several other institutional investors have also recently added to or reduced their stakes in the business. Advisory Services Network LLC acquired a new position in shares of Globus Medical during the 3rd quarter valued at about $26,000. EverSource Wealth Advisors LLC boosted its position in shares of Globus Medical by 74.3% in the second quarter. EverSource Wealth Advisors LLC now owns 462 shares of the medical device company’s stock worth $27,000 after acquiring an additional 197 shares during the last quarter. SBI Securities Co. Ltd. boosted its position in shares of Globus Medical by 98.2% in the fourth quarter. SBI Securities Co. Ltd. now owns 337 shares of the medical device company’s stock worth $29,000 after acquiring an additional 167 shares during the last quarter. Parallel Advisors LLC grew its holdings in Globus Medical by 45.1% in the third quarter. Parallel Advisors LLC now owns 557 shares of the medical device company’s stock valued at $32,000 after purchasing an additional 173 shares during the period. Finally, Headlands Technologies LLC grew its holdings in Globus Medical by 485.4% in the second quarter. Headlands Technologies LLC now owns 761 shares of the medical device company’s stock valued at $45,000 after purchasing an additional 631 shares during the period. 95.16% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

GMED has been the topic of a number of research analyst reports. Royal Bank Of Canada lifted their price target on shares of Globus Medical from $115.00 to $120.00 and gave the company an “outperform” rating in a report on Friday, May 8th. Wells Fargo & Company dropped their price objective on Globus Medical from $104.00 to $103.00 and set an “overweight” rating for the company in a report on Friday, May 8th. Wall Street Zen lowered Globus Medical from a “strong-buy” rating to a “buy” rating in a research report on Saturday, May 9th. Stifel Nicolaus lowered their price target on Globus Medical from $95.00 to $80.00 and set a “hold” rating for the company in a research report on Wednesday. Finally, Piper Sandler lowered their price target on Globus Medical from $115.00 to $100.00 and set an “overweight” rating for the company in a research report on Monday, June 15th. One equities research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating and five have given a Hold rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $105.42.

Insider Buying and Selling at Globus Medical

In other news, Director David D. Davidar sold 25,000 shares of the stock in a transaction dated Friday, June 5th. The stock was sold at an average price of $80.76, for a total value of $2,019,000.00. Following the completion of the sale, the director owned 510,175 shares in the company, valued at approximately $41,201,733. This trade represents a 4.67% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 18.38% of the stock is owned by insiders.

Globus Medical Trading Down 3.3%

Shares of GMED stock opened at $76.23 on Thursday. The company has a market cap of $10.35 billion, a PE ratio of 17.73, a P/E/G ratio of 1.63 and a beta of 0.95. The company’s fifty day simple moving average is $81.13 and its 200-day simple moving average is $86.97. Globus Medical, Inc. has a 52 week low of $51.79 and a 52 week high of $101.40.

Globus Medical (NYSE:GMED) last announced its quarterly earnings results on Thursday, May 7th. The medical device company reported $1.12 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.92 by $0.20. Globus Medical had a return on equity of 13.46% and a net margin of 18.92%.The firm had revenue of $759.85 million during the quarter, compared to the consensus estimate of $740.35 million. During the same period in the prior year, the firm earned $0.68 EPS. The firm’s quarterly revenue was up 27.0% compared to the same quarter last year. Globus Medical has set its FY 2026 guidance at 4.700-4.800 EPS. Equities research analysts expect that Globus Medical, Inc. will post 4.74 EPS for the current fiscal year.

Globus Medical Company Profile

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.